Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain

Journal of Neuroscience Research

Volumn 85, Issue 4, 2007, Pages 757-765

  Narayan, Sujatha ^a   Kass, Kristi E ^a   Thomas, Elizabeth A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antipsychotic; Dopamine; Haloperidol; Oligodendrocyte; Schizophrenia; White matter

Indexed keywords

CLOZAPINE; HALOPERIDOL; MYELIN;

ARTICLE; BRAIN REGION; CONTROLLED STUDY; DENSITOMETRY; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; PRIORITY JOURNAL; SCHIZOPHRENIA; WHITE MATTER;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; HALOPERIDOL; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C57BL; MYELIN-ASSOCIATED GLYCOPROTEIN; NERVE TISSUE PROTEINS;

EID: 33947217962     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21161     Document Type: Article

References (53)

1. Antonova E, Kumari V, Morris R, Halari R, Anilkumar A, Mehrotra R, Sharma T. 2005. The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study. Biol Psychiatry 58:457-467.
2. Aston C, Jiang L, Sokolov BP. 2004. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77: 858-866.
3. Bartzokis G. 2002. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology 27:672-683.
4. Baumann N, Pham-Dinh D. 2001. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81:871-927.
5. Bongarzone ER, Howard SG, Schonmann V, Campagnoni AT. 1998. Identification of the dopamine D3 receptor in oligodendrocyte precursors: potential role in regulating differentiation and myelin formation. J Neurosci 18:5344-5353.
6. Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS. 2002. Typical antipsychotic drugs - D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 56:31-36.
7. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
8. Campbell A, Baldessarini RJ, Cremens MC. 1988. Dose-catalepsy response to haloperidol in rat: effects of strain and sex. Neuropharmacology 27:1197-1199.
9. Carlsson A, Lindqvist M. 1963. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramme and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144.
10. Chong VZ, Young LT, Mishra RK. 2002. cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J Neurochem 82:1533-1539.
11. Creese I, Burt DR, Snyder SH. 1976. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483.
12. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. 2003. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60:443-456.
13. de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. 2000. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 157:1019-1020.
14. Delarasse C, Daubas P, Mars LT, Vizier C, Litzenburger T, Iglesias A, Bauer J, Della Gaspera B, Schubart A, Decker L, Dimitri D, Roussel G, Dierich A, Amor S, Dautigny A, Liblau R, Pham-Dinh D. 2003. Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest 112:544-553.
15. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. 2006. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21:531-540.
16. Fasulo WH, Hemby SE. 2003. Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration. J Neurochem 87:205-219.
17. Fuster JM. 2001. The prefrontal cortex - an update: time is of the essence. Neuron 30:319-333.
18. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98:4746-4751.
19. Harrison PJ, Weinberger DR. 2005. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68 [image 45].
20. Hof PR, Haroutunian V, Friedrich VL Jr, Byne W, Buitron C, Perl DP, Davis KL. 2003. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 53:1075-1085.
21. Howard S, Landry C, Fisher R, Bezouglaia O, Handley V, Campagnoni A. 1998. Postnatal localization and morphogenesis of cells expressing the dopaminergic D2 receptor gene in rat brain: expression in non-neuronal cells. J Comp Neurol 391:87-98.
22. Jann MW. 1991. Clozapine. Pharmacotherapy 11:179-195.
23. Kanes SJ, Hitzemann BA, Hitzemann RJ. 1993. On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice. J Pharmacol Exp Ther 267:538-547.
24. Katsel PL, Davis KL, Haroutunian V. 2005. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. Int Rev Neurobiol 63:41-82.
25. Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, Niznikiewicz M, Connor EE, Levitt JJ, Frumin M, Kikinis R, Jolesz FA, McCarley RW, Shenton ME. 2005. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 26:1109-1118.
26. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave KA. 2003. Disruption of Cnpl uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 33:366-374.
27. Lewis DA, Lieberman JA. 2000. Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-334.
28. MacDonald ML, Eaton ME, Dudman JT, Konradi C. 2005. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 57:1041-1051.
29. Mehler-Wex C, Grunblatt E, Zeiske S, Gille G, Rausch D, Warnke A, Gerlach M. 2006. Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. J Neural Transm 113:1383-1393.
30. Meltzer HY, Nash JF. 1991. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604.
31. Mimics K, Levitt P, Lewis DA. 2006. Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry (in press).
32. Moller HJ, Bottlender R, Wegner U, Wittmann J, Strauss A. 2000. Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. Acta Psychiatry Scand Suppl 407:54-57.
33. Ninan I, Kulkarni SK. 1996. Clozapine-induced cognitive dysfunction in mice. Methods Find Exp Clin Pharmacol 18:367-372.
34. Pietraszek M, Golembiowska K, Bijak M, Ossowska K, Wolfarth S. 2002. Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies. Naunyn-Schmiedebergs Arch Pharmacol 366:417-424.
35. Pongrac J, Middleton FA, Lewis DA, Levitt P, Mimics K. 2002. Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders. Neurochem Res 27:1049-1063.
36. Rosengarten H, Quartermain D. 2002. Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats. Pharmacol Biochem Behav 72:575-579.
37. Rosin C, Colombo S, Calver AA, Bates TE, Skaper SD. 2005. Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia 52:336-343.
38. Saeedi H, Remington G, Christensen BK. 2006. Impact of haloperidol, a dopamine D(2) antagonist, on cognition and mood. Schizophr Res (in press).
39. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wolkin A. 2000. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 57:471-480.
40. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. 1995. The role of 5-HT2A receptors in antipsychotic activity. Life Sci 56:2209-2222.
41. Seeman P, Lee T. 1975. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219.
42. Sherman DL, Brophy PJ. 2005. Mechanisms of axon ensheathment and myelin growth. Nat Rev Neurosci 6:683-690.
43. Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C, Nakamura R, Kakita A, Takahashi H, Nawa H. 2004. Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann N Y Acad Sci 1025:84-91.
44. Thomas EA, Yao JK. 2006. Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D. Schizophr Res (in press).
45. Thomas EA, George RC, Danielson PE, Nelson PA, Warren AJ, Lo D, Sutcliffe JG. 2003. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry 8:983-993, 950.
46. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S. 2003. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:798-805.
47. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. 2004. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 67:269-275.
48. van Rossum JM. 1966. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160:492-494.
49. Voruganti L, Awad AG. 2004. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 171:121-132.
50. Walker E, Kestler L, Bollini A, Hochman KM. 2004. Schizophrenia: etiology and course. Annu Rev Psychol 55:401-430.
51. Wible CG, Anderson J, Shenton ME, Kricun A, Hirayasu Y, Tanaka S, Levitt JJ, O'Donnell BF, Kikinis R, Jolesz FA, McCarley RW. 2001. Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatry Res 108:65-78.
52. Yan Z, Feng J, Fienberg AA, Greengard P. 1999. D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc Natl Acad Sci U S A 96:11607-11612.
53. Zanassi P, Paolillo M, Feliciello A, Avvedimento EV, Gallo V, Schinelli S. 2001. cAMP-dependent protein kinase induces cAMP-response element-binding protein phosphorylation via an intracellular calcium release/ERK-dependent pathway in striatal neurons. J Biol Chem 276:11487-11495.